Update on rheumatic manifestations of infectious diseases

Current Opinion in Rheumatology

Volumn 22, Issue 1, 2010, Pages 72-77

  Becker, Jennifer ^a   Winthrop, Kevin L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Arthritis; Bacteria; Infection; Vasculitis; Virus

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB;

ARTHRITIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CHIKUNGUNYA ALPHAVIRUS; CHLAMYDIASIS; CLINICAL FEATURE; CRYOGLOBULINEMIA; DRUG EXTRAVASATION; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; MEASLES; MEASLES VIRUS; NEUTROPENIA; PARVOVIRUS; PRIORITY JOURNAL; REACTIVE ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SPONDYLARTHRITIS; SYMPTOM; VASCULITIS; VIRUS INFECTION;

ALPHAVIRUS INFECTIONS; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; BACTERIAL INFECTIONS; CHLAMYDIA INFECTIONS; COMMUNICABLE DISEASES; HEPATITIS C; HUMANS; RHEUMATIC DISEASES; VIRUS DISEASES;

EID: 73649111753     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328333b9f5     Document Type: Review

References (40)

1. Keil H. Relationship between lupus erythematosus and tuberculosis. Arch Derm 1933; 28:765-779.
2. Forestier J. Rheumatoid arthritis and its treatment with gold salts. J Lab Clin Med 1935; 20:827-840.
3. Colmegna I, Alberts-Grill N. Parvovirus B19: Its role in chronic arthritis. Rheum Dis Clin North Am 2009; 35:95-110.
4. Wilkinson NZ, Kinglsley GH, Jones HW, et al. Detection of DNA from range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. Rheumatology 1999; 38:260-266.
5. Hill Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 1999; 42:2239-2242.
6. Carter J, Hudson A. Reactive arthritis: Clinical aspects and medical management. Rheum Dis Clin N Am 2009; 35:21-44.
7. Townes JM, Deodhar AA, Laine ES, et al. Reactive Arthritis following cultureconfirmed infections with bacterial enteric pathogens in Minnesota and Oregon: A population-based study. Ann Rheum Dis 2008; 67:1689-1696.
8. Locht H, Krogfelt KA. Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli. Ann Rheum Dis 2002; 61:448-452.
9. Locht H, Kilstrom E, Lindstrom FD. Reactive arthritis after Salmonella among medical doctors: A study of an outbreak. J Rheumatol 1993; 20:845-848.
10. Garg AX, Pope JE, Thiessen-Philbrook H, et al. Arthritis risk after acute bacterial gastroenteritis. Rheumatology 2008; 47:200-204.
11. Schiellerup P, Krogfelt K, Locht H. A Comparison of self-reported joint symptoms following infection with different enteric pathogens: Effect of HLA-B27. J Rheumatol 2008; 35:480-497.
12. Rohekar S, Tsui FWL, Tsui HW, et al. Symptomatic acute reactive arthritis after an outbreak of Salmonella. J Rheumatol 2008; 35:1599-1602.
13. Whittum-Hudson JA, Hudson AP. Human chlamydial infections: persistence, prevalence, and prospects for the future. Nat Sci Soc 2005; 13:371-382.
14. Carter JD, Gérard HC, Espinoza LR, et al. Chlamydia as etiologic agents in chronic undifferentiated spondyloarthritis. Arthritis Rheum 2009; 60:1311-1316.
15. Chen YS, Chou PH, Li SN, et al. Parvovirus B19 infection in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2006; 33:887-891.
16. Murai C, Munakata Y, Takahashi Y, et al. Rheumatoid arthritis after human parvovirus B19 infection. Ann Rheum Dis 1999; 58:130-132.
17. Soderlund M, von Essen R, Haapasaari J, et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997; 349:1063-1065.
18. Kerr JR, Cartron JP, Curran MD, et al. A study of the role of parvovirus B19 in rheumatoid arthritis. Br J Rheumatol 1995; 34:809-813.
19. Vassilopoulos D, Calabrese L. Virally associated arthritis 2008: Clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 2008; 10:1-8.
20. Soderlund-Venermo M, Hokynar K, Nieminen J, et al. Persistence of human parvovirus B19 in human tissues. Pathol Biol 2002; 50:307-316.
21. Rosenau BJ, Schur PH. Association of measles virus with rheumatoid arthritis. J Rheumatol 2009; 36:893-897.
22. Hassidim A, et al. Centers for disease control and prevention. Outbreak of measles-San Diego, California, Jan-Feb 2008. MMWR Morb Mortal Wkly Rep 2008; 57:203-206.
23. Hutchins S, Bellini WJ, Coronado V, et al. Polulation immunity to measles in the United States, 1999. J Infect Dis 2004; 189 (Suppl 1):S91-S97. (Pubitemid 38639575)
24. Helmick C, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 2008; 58:15-25.
25. Buskila D. Hepatitis C-associated rheumatic disorders. Rheum Dis Clin N Am 2009; 35:111-123.
26. Terrier B, Saadoun D, Sène D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virusrelated vasculitis. Arthritis Rheum 2009; 60:2531-2540.
27. Ramos-Casals M, Munõz S, Medina F, et al. Systemic autoimmune diseases in patients with hepatitis C virus infection: Characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36:1442-1448.
28. Bombardieri M, Alessandri C, Iannuccelli C, et al. Role of anticyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6:R137-R141.
29. Lim MK, Sheen DH, Lee YJ, et al. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection. J Rheumatol 2009; 36:712-716.
30. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63:18-24.
31. Parke FA, Reveille JD. Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800-804.
32. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of antitumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35:1944-1949.
33. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective record review of 11 patients. Clin Rheumatol 2009; 28:787-791.
34. Toivanen A. Alphaviruses: An emerging cause of arthritis. Curr Opin Rheumatol 2008; 20:486-490.
35. Suhrbier A, Linn M. Clinical and pathological aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol 2004; 16:374-379.
36. Gould EA, Higg S. Impact of climate change and other factors on emerging arbovirus diseases. Trans Roy Soc Trop Med Hyg 2009; 103:109-121.
37. Carmona RJ. Chikungunya viral polyarthritis. J Rheumatol 2008; 35:935-936.
38. Calabrese LH. Emerging viral infections and arthritis: The role of the rheumatologist. Nat Clin Pract Rheumatol 2008; 4:2-3.
39. Tappe D, Schmidt-Chanasit J, Ries A, et al. Ross River virus infection in a traveler returning from northern Australia. Med Microbiol Immunol 2009. [Epub ahead of print]
40. Sudeep AB, Parashar D. Chikungunya: An overview. J Biosci 2008; 33:443-449.